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com (S.F.D. Paul).During the last three decades, a number of B-lymphocyte speciﬁc surface antigens have been deﬁned
some of which may also show activation/differentiation speciﬁc expression. Here, we review the var-
ious signaling events and the receptor-ligand interactions for B-cell development, activation and
differentiation. Our discussion and presentation include reviewing the in vivo and in vitro mecha-
nisms. Focus is on the experiments that give us valuable insights into the B cell signaling mecha-
nisms in vitro. Three signiﬁcant pathways in B-cell development – c-Kit, FLT-3 and IL-7 signaling
pathways are elucidated upon. Both antigen dependent and antigen independent mechanisms of
B cell stimulation are also reviewed.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction takes a path going through several stages for development, activa-B-Lymphocytes are the antibody producing subset of lympho-
cytes and account for 5–15% of the circulating lymphoid cells. B
cells also are antigen presenting cells which make them an inter-
esting link between the humoral and cell mediated immune re-
sponses. They mature in the bone marrow and play a major role
in the development of humoral immune responses. From birth as
a hematopoietic stem cell lodged in the bone marrow, the B cellchemical Societies. Published by E
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addaly), wise_soly@yahoo.-tion, proliferation and differentiation into the effector antibody
secretory plasma cell or the crucial memory cell. Richard Hardy
and colleagues divided B cell precursors into subpopulations—the
Hardy fractions—based on the cells’ expression of various cell sur-
face proteins in the order of their differentiation from progenitor
B cell (pro-B) to precursor B cell (pre-B) to mature B-cells in the
early 1990s. This classiﬁcation helped lay the groundwork for our
present-day understanding of the molecular events that control
early B-cell development [1]. Each of the developmental stages
namely the stem cell, pro-B, pre-B, immature and mature B cell
are marked by well orchestrated signaling mechanisms mediated
by speciﬁc receptors and corresponding ligands. Not only the se-
quence but also the checkpoints and selection processes, both po-
sitive and negative, at speciﬁc stages throughout the B-cell
development ensures that its physiological primary function for
adaptive immunity is ensured. The experiments of in vitro immu-
nization towards the murine and human monoclonal antibody
(MAb) development have given us major insights in understanding
the B cell better. The roles of various speciﬁc factors/molecules and
also media supplements such as conditioned medium, co-culture,
feeder cells etc. are valuable leads in this direction. Protocols
adopted for in vitro stimulation of in vivo primed lymphocytes also
give us a new avenue towards the same and ﬁlls in certain key
areas, especially the memory sub-set of B-cell development as use-
ful for secondary responses.lsevier B.V. All rights reserved.
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stimulators of naïve/memory B cells for obtaining differentiated
and functional plasma cells in vitro are valuable in our understand-
ing of the B-cell development. Concanavalin-A bound to Agarose
beads was found to be an effective B cell mitogen. In our studies,
we directed membrane Ig+ B cells from human peripheral circula-
tion selectively to such beads using Antihuman immunoglobulin G
(IgG) HRP conjugate considering the high afﬁnity of Concanavalin-
A to HRP. Such cells with culture supplementations of select
growth/development factors showed interesting results in mor-
phology, function, behaviour and enhanced proliferation capabili-
ties. While this can be a good model for obtaining differentiated,
functional plasma cells, it also provides us with a model system
to understand the activation and further development of B cells,
especially the antigen dependent mechanisms.
In this review, we present all the major areas that gave valuable
insights into understanding the receptors and the signaling path-
ways of B-cell development, activation, proliferation and differen-
tiation. The in vivo mechanisms, the in vitro experiments related to
generating antibody producing cells and ﬁnally the role of experi-
ments which utilized non-antigenic methods for activation, prolif-
eration and differentiation of B cells in vitro are included. The
mechanisms of B-cell development from both murine and human
systems were included as they share many important developmen-
tal events. Three key signaling mechanisms, the c-kit, Flt-3 and IL-7
are found crucial for B-cell development and are included in this
review. The synergistic interplay of these signaling mechanisms
seem to complement one another (evident from their independent
insufﬁciency in B-cell development), making them ‘indispensable’
to early B-cell development.2. Receptors and signaling mechanisms in vivo
2.1. Development of B cells
The development of the B cells can be classiﬁed into two stages
– the antigen independent stage and a stage that is dependent on B
cell contact with a foreign molecule.
2.1.1. Antigen independent development
The development of B cells takes place in the fetal liver and con-
tinues in the bone marrow of an adult. The formation of a mature B
cell involves a number of phenotypically distinct precursor cells;
parallel immunoglobulin gene rearrangements (VDJ) contribute to
diversity in antigen recognition among mature B-lymphocytes.
The ﬁrst to arise from a common lymphoid progenitor (CLP) is the
pro-B cell; requiring direct contactwith bonemarrow stroma (niche
microenvironment) initially, followedby several growth-promoting
signals ultimately through IL-7 which drives maturation. As they
progress through the pro-B cell stage, Immunoglobulin heavy chain
mu (l) gene rearrangement ensues, from DH to JH ﬁrst, followed by
the joining of rearranged VH to DHJH. Such rearrangement proceeds
on one of the chromosomes (14 in human) and involves the second
chromosome only if the ﬁrst rearrangement is ‘unproductive’. ‘Pro-
ductive’ rearrangement renders the cells to the pre-B cell stage,
characterized by cell surface pre-B cell receptor, comprising of rear-
ranged l heavy chain along with surrogate light chains (k5, Vpre-B)
and the signal transducing Iga/Igb. Productive light chain Kappa (j)
gene rearrangement prevents lambda (k) genes from rearranging by
allelic exclusion, resulting in the formation of immature B cells with
a complete membrane-bound IgM (mIgM+) speciﬁc to a particular
antigen. Differential RNA processing and appropriate polyadenyla-
tion of the primary heavy chain transcript then allows mature B
cells to simultaneously express both immunoglobulin M (IgM)
and immunoglobulin D (IgD) on the cell membrane.2.1.2. B Cell receptor
Naive B-lymphocytes possess a membrane-bound antibody,
usually IgM and IgD, as its receptor. The B-cell receptors (BCRs)
bind to epitopes on soluble antigens – the ligand recognition por-
tion (Paratope) of the BCR complex. In presence of accessory sig-
nals, this binding will result in the activation of the B cell and
subsequent antibody production. A vast repertoire of antigenic epi-
topes and conserved signaling pathways for B cell activation post
epitope-binding irrespective of the nature of the epitope, necessi-
tates functional distinction at the cytoplasmic end; the Iga/Igb
disulﬁde-linked heterodimer (one associated with every mIg), par-
ticularly an 18 residue motif at its tail called the ITAM, similar to
that found in the T-cell receptor complex, forms the signal trans-
duction component of the BCR complex. The activated BCR com-
plex recruits protein tyrosine kinases for signal relay and
ampliﬁcation. Each B-lymphocyte has on an average, 1.5  105
membrane-bound antibody molecules capable of recognizing the
same epitope. Immunoglobulin light chains (k and j) and heavy
chains are encoded on human chromosomes 22, 2 and 14, respec-
tively. Each contains numerous gene segments. Light chain gene
segments are V and J and heavy chains have an additional D seg-
ment. Gene segments undergo rearrangements during B-cell devel-
opment – a process that is responsible for antibody diversity.
2.2. Activation of B cells – antigen dependent development
The activation of a B cell varies depending on the type of antigen
that it interacts with.
2.2.1. T-Independent antigens (TI antigens)
These antigens do not require contact with T helper cells in or-
der to activate the B-lymphocytes. These are further divided into
two types. T-Independent antigen type 1 (TI-1) are polyclonal acti-
vators of B cells. They are capable of non-speciﬁc activation of B
cells at high concentrations and stimulating both mature and
immature B cells. Example of a TI-1 antigen is bacterial lipopoly-
saccharides. T-Independent type 2 (TI-2) antigens require cyto-
kines secreted by T helper cells for their activation, but not direct
contact with them. Bacterial polysaccharides, polymeric bacterial
ﬂagellin etc. which have repeating antigenic determinants are usu-
ally TI-2 antigens. The response to a TI antigen is weak and usually
produces only IgM. The secondary response to TI resembles the pri-
mary response. The lack of co-stimulation of clusters of differenti-
ation (CD) 40 may be a reason why TI antigens fail to produce class
switching and an increase in antibody afﬁnity. Poor memory re-
sponse is also characteristic of TI antigens. These antigens predom-
inantly activate the B-1 subset of B cells.
2.2.2. T-Dependent antigens (TD antigens)
Such antigens are dependent on T helper cells and cytokines
produced by them for the activation of the B cells. They are usually
soluble protein antigens. T Helper cells are activated by presenta-
tion of antigenic peptides on class II major histocompatibility com-
plex (MHC). The epitopes on the same antigen recognized by the T
and B cells are very different. The encounter between a B-lympho-
cyte that has been stimulated by antigen and a T helper cell takes
place in the secondary lymphoid organs.
2.3. T Helper cell and B cell interaction – response to a T-dependent
antigen
When a T-dependent antigen is involved, the interaction be-
tween the T and B cells is important for the activation of the latter.
The encounter of a B cell and an antigen leads to the expression of
several cell surface markers on the B cell surface. This includes B 7
and MHC class II if the B cell is itself acting as the antigen present-
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are low. Once the T cell is activated by interaction with the anti-
genic peptide on class II MHC, it transiently expresses the CD 40 li-
gand (CD 40L) which belongs to the TNF family. The ligand
interacts with the CD 40 receptor on the B cell. This acts as a pro-
gression signal for entry of G1 stage B-lymphocytes into the S
phase. CD 40 also up-regulates CD 80 and CD 86 which provide
co-stimulatory signals to the T cells. Cytokines secreted by T helper
cells that stimulate B cells include IL-2 and interferon-c (IFN-c) by
TH1 cells and IL-4, IL-5, IL-6, IL-10, IL-13 by TH2 cells. IL-4 known
previously as B cell differentiation factor 1, induces B cell activa-
tion and differentiation, as well as TH2 differentiation. IL-6 previ-
ously known as B cell differentiation factor stimulates formation
of antibody forming cells. IL-10 acts as a growth factor and IL-7
supports B cell growth.
2.4. Progression through the cell cycle
Two signals are required to break the quiescent status of a B
cell. The ﬁrst is called a competence signal. Antigen cross-linking
brings about the activation of src family of kinases and down-
stream events are initiated which results in the translocation of
nuclear transcription factors that suitably alter gene expression.
The signal transduction involves the ITAMs on the BCR which help
by recruiting the downstream signaling molecules. The co-receptor
complex comprising CD 21, CD 19 and CD 81 augment B cell acti-
vation. Once competence is achieved, the cell progresses from G0
to G1 stage of the cell cycle. The second signal, the progression sig-
nal then pushes the G1 stage B cells into the S phase, by its inter-
action with accessory ligands and cytokines.
2.5. B Cell differentiation
2.5.1. Differentiation into short lived, low afﬁnity plasma cells
Small foci of proliferating B cells form at the T cell rich edge of
the secondary lymphoid organ. These proliferating cells differenti-
ate into plasma cells that secrete low afﬁnity antibodies, usually of
the IgM type, which are involved in the primary response.
2.5.2. Differentiation into high afﬁnity plasma cells and memory cells –
class switch and somatic hypermutation
In the case of a T-dependent antigen, a few days after foci for-
mation, some B cells along with a few T helper cells move into
the primary follicles of the lymphoid organs. The primary follicles
then mature into secondary follicles in the centre of which a germi-
nal centre forms. Here, the B cells undergo intense proliferation.
The proliferating B cells are called centroblasts and they form a
dark zone in the germinal centre Random point mutations, dele-
tions and insertions in the variable region immunoglobulin genes
take place in the rapidly dividing centroblasts. The mutation rate
is 103/base pair/division. The mutations produce a large number
of centroblasts which have altered afﬁnities to the same antigen
that was recognized by the parent B cell. Centroblasts down-regu-
late their surface immunoglobulin expression. Eventually, these
give rise to centrocytes which migrate to light zones rich in follic-
ular dendritic cells and begin to express surface BCR again. The
centrocytes compete with each other to bind antigen on the anti-
gen–antibody complex on follicular dendritic cells. Only those with
high afﬁnity get selected. The ones that do not pass selection un-
dergo Fas-mediated apoptosis. The selected cells receive survival
signals from the dendritic cells and also from T helper cells. Class
switching (for thymus dependant antigens) depends on several
factors such as the cytokines and interaction of CD 40-CD 40L.
The switch involves rearrangements only in the constant regions
of the heavy chain and this retains antigenic speciﬁcity.The hematopoietic development along with the expression of
differentiation markers during the B-cell development are detailed
in Fig. 1 and the stage speciﬁc differentiation markers and corre-
sponding events are given in Table 1.
2.6. Key signaling mechanisms, the c-Kit, FLT-3 and IL-7 signaling
The signaling mechanisms of c-kit, Flt-3 and IL-7 are known to
play a key role in early B-cell development. Several independent
studies reveal that the synergistic yet unique and non-redundant
activities of these three signaling pathways promote hematopoi-
etic stem cell (HSC) survival and growth/proliferation and drive
B-lineage commitment and differentiation. The master transcrip-
tional regulatory network that governs B-cell development, com-
prising of factors PU.1, Ikaros, E2A and EBF, more precisely PU.1
and Ikaros act in parallel to control development of lymphoid pro-
genitors, in part by directly regulating expression of essential sig-
naling receptors c-kit, Flt-3 and IL-7Ra. The overlapping cascade
of c-kit and Flt-3 signaling is reported to be essential for stem/pro-
genitor cell survival and proliferation (self-renewal), while the un-
ique effects of Ras-mediated Flt-3 signaling primes B-lineage
development by establishing a state of cellular IL-7 responsiveness
for the subsequent STAT5-dependent B-cell differentiation. More-
over, currently practiced methods for in vitro directed differentia-
tion of multipotent haematopoietic progenitors to B-lymphocytes
successfully employ ligands for c-Kit, Flt-3 and IL-7Ra in stromal
co-cultures. The synergistic interplay of these signaling mecha-
nisms seem to complement one another (evident from their inde-
pendent insufﬁciency in B-cell development), making them
‘indispensable’ to early B-cell development.
2.6.1. c-KIT signaling
The c-KIT/SF system plays an important role in the very early
stages of development of lymphocytes in the mouse, as it does at
different levels in various cell types in the hematopoietic hierar-
chy. The c-Kit gene encodes a 145-kDa transmembrane protein that
is a member of the receptor tyrosine kinase subclass III family that
includes the platelet-derived growth factor receptor (PDGF-R),
macrophage colony-stimulating factor receptor (M-CSF-R or cfms),
and the fms-like tyrosine kinase-3/fetal liver kinase-2 (Flt-3/Flt-2).
Attenuating mutations in the c-Kit locus (white spotted or W mu-
tants) lead to a lethal anemia, HSC defects, mast cell deﬁciency, as
well as a series of non-hematologic defects in mice.
The ligand for c-KIT, steel factor (SF), which is also known as kit
ligand, stem cell factor, and mast cell growth factor, is a transmem-
brane growth factor encoded by the Sl gene and can be expressed
as different isoforms with different activities and can be cleaved
proteolytically to yield soluble forms with similar binding afﬁnity.
The expression of SF in stromal cells is subject to complex regula-
tion by other cytokines produced by the same stromal cells or by
neighbouring cells in a given microenvironment. The soluble form
appears to be most important for biologic activity in vitro, while
the membrane-bound form is of importance in vivo. Mice deﬁcient
in SF expression (Steel or Sl mutants) show similar defects as W
mice including in utero lethality due to severe anemia. The mast
cell deﬁciency, together with the observation that the entire hema-
topoietic progenitor/stem cell pool in viable W and Sl mutants is
compromised, suggests that c-KIT signaling is important at many
different levels in the hematopoietic hierarchy.
Binding of SF to the c-KIT receptor induces receptor homodi-
merization and auto crossphosphorylation of tyrosine residues in
the cytoplasmic domain, which then serve as docking sites for var-
ious SH2 domain-containing signaling intermediates. As a result of
c-KIT activation by SF, proteins of the Ras/Erk and the phosphoin-
ositide-3 kinase (PI3K) pathways are subsequently activated.
Fig. 1. Panel 1a. Haematopoeisis in mouse. The panel depicts the sequential sites of haematopoietic activity beginning from ventral mesodermally derived haematopoietic
stem cells (HSCs); including the yolk sac, the aorta-gonad-mesonephros (AGM) region, the fetal liver, placenta, and ﬁnally the bone marrow. Differences in HSC properties in
each site reﬂect the diverse developmental (expansion- and/or differentiation-supporting) niches. ‘‘Primitive” haematopoiesis begins in the mammalian yolk and goes on
through the hemogenic endothelial cells (ECs) in the AGM and the placenta. However, the relative contribution of each of the above sites to the ﬁnal HSC pool remains yet
unknown. ‘‘Deﬁnitive” haematopoiesis ensues after colonization of the fetal liver, thymus, spleen and ultimately in the bone marrow, where short-term HSCs arising from long-
term, self-renewing HSCs give rise to the common myeloid- (CMPs) and common lymphoid progenitors (CLPs) respectively. CLPs produce committed B- and T-lymphocyte
progenitors, while CMPs are a source of megakaryocyte/erythroid progenitors (MEPs) and granulocyte/macrophage progenitors (GMPs). GMPs give rise to committed
precursors of mast cells, eosinophils, neutrophils and macrophages. [54–56]. Panel 1b. Stages of B-lymphocyte development in vivo. The panel illustrates the step-wise
progression of haematopoietic development along the B-cell lineage in vivo. The changing pattern of cell surface markers that typify the developmental progression from
stem/progenitor to mature cell in both human and mice are indicated alongside. The lower part represents ‘expression levels’ of various surface proteins majority of which are
currently in use as markers for immunohistochemical identiﬁcation and ﬂow cytometric isolation [57,58]. [Source: Orkin and Zon, Cell 132, 2008]
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dependent pathway is essential for SF-induced Erk activation in
HSCs. Activation of KIT also results in the recruitment and activa-
tion of adjacent kinases including JAK2 and MATK; the tyrosine
phosphatases SHP-1 and SHP-2; phospholipase C; and the p85 sub-
unit of PI3K. The subsequent assembly of a functional PI3K holoen-
zyme leads to the activation of cytosolic PDK1 and AKT/PKB. The
accompanying reduction in PTEN levels then reinforces the initia-
tion of multiple downstream events along the PI3K pathwayincluding inactivation of the forkhead transcription factor O3A
and activation of the mitogen-activated protein kinase pathway
(MAP Kinase). SF-mediated activation of JAK2 leads, in turn, to
the activation of STATs 1, 3, and 5, which then form dimers and
translocate to the nucleus to alter the transcription of speciﬁc tar-
get genes. It is thought that some of these signaling elements and
their ultimate transcriptional targets seem to participate in the
regulation of HSC survival and self-renewal control [2–4]. The tran-
scription factors effective for B-cell development along with a
Table 1
The stage speciﬁc differentiation markers and corresponding characteristic features of B-cell development involving the receptor/signaling mechanisms.
Cell stage Surface marker Stage speciﬁc features
Haematopoietic
stem cells
CD 34, CD 43, CD 117 Germline immunoglobulin genes
Differentiates into lymphoid as well as myeloid progenitors
Lymphoid progenitors develop into T and B cells
Early pro-B
cells
CD 34, CD 43, CD 117, B 220/CD 45R, CD 127,
CD179A/B, MHC CLASS II
Early pro-B cells -terminal deoxynucleotidyl transferase (TdT) – necessary for N nucleotide
substitutions in the DH-JH and VH-DHJH coding joints
Intermediate pro-B cells – B 220, TdT. B 220 – important for the recognition of a particular
splice variant of a leukocyte antigen – CD45R (important for B cell signaling)
l heavy chain D-J joining
RAG1 and RAG2, CD 43 (leukosialin) and CD 19 expression
Late pro-B cells CD 19, CD 24, CD 40, CD 43, CD 117, B 220/CD 45R,
CD 127, CD179A/B, MHC CLASS II
Down-regulated TdT, B 220 remains throughout the rest of the B cell ontogeny
l heavy chain V-D-J joining
Large Pre-B
cells
CD 19, CD 24, CD 25, CD 40, CD 43, CD 117, B 220/
CD 45R, CD 127, CD179A/B, MHC CLASS II
l chain in pre b cell receptor
j VJ rearrangement (if not productive – k VJ rearrangement)
RAG1 and RAG2, CD 43 (leukosialin) and CD 19 down-regulated
Small Pre-B
cells
CD 19, CD 24, CD 25, CD 40, B 220/CD 45R, CD 127,
MHC CLASS II
RAG1 and RAG2, CD 43 (leukosialin) and CD 19 expression
Immature B
cells
CD 19, CD 24, CD 40
B 220/CD 45R, MHC CLASS II
Differential rna processing and appropriate polyadenylation of primary transcript
Leaves the bone marrow, enters the peripheral circulation
RAG1 and RAG2, CD 43 (leukosialin) and CD 19 expression
Mature B cells CD 19, CD 21, CD 22, CD 23, CD 24, CD 40, B 220/CD
45R, MHC CLASS II
RAG1 and RAG2, CD 43 (leukosialin) and CD 19 down-regulation
Expression of both membrane IgM and IgD is necessary for the B cell to become fully
functional, else activation results in apoptosis or unresponsiveness
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development are given in Fig. 2.
2.6.2. FLT-3 signaling
Fms-like tyrosine kinase 3 (FLT3) is also known as fetal liver ki-
nase-2 (FLK-2) and human stem cell kinase-1 (STK-1). FLT3 has
strong sequence similarities with other members of the class III
receptor tyrosine kinase (RTKIII) receptor family and is character-
ized by an extracellular domain comprising of ﬁve immunoglobu-
lin-like (Ig-like) domains and a cytoplasmic domain with a split
tyrosine kinase motif. The Flt3 gene encodes a 1000– and 993–ami-
no acid protein in the mouse and human, respectively, and is ex-
pressed in immature hematopoietic cells, placenta, gonads, and
brain. In normal bone marrow, expression appears to be restricted
to early progenitors, including CD34+ cells with high levels of
expression of CD117 (c-KIT).
Targeted disruption of Flt3 in mice, however, results in deﬁcien-
cies in primitive B-lymphoid progenitors and poor multi-lineage
reconstitution after bone marrow transplantation (BMT) despite
possessing a healthy adult hematopoietic population, pointing to
its important synergistic role in development of multipotent stem
cells and B cells.
The ligand for FLT3 (FLT3 ligand or FL) is a type I transmem-
brane (TM) protein that can be released as a soluble homodimeric
protein (alternative splice variant), and is expressed in cells of the
hematopoietic bone marrow microenvironment, including bone
marrow ﬁbroblasts as well as in hematopoietic cell lines of mye-
loid, and B and T cell lineages. Both the membrane-bound and sol-
uble forms can activate the tyrosine kinase activity of the receptor.
However, the membrane-bound form is more pertinent in vivo,
while the secreted ligand dimer is able to cooperatively stimulate
expansion of CD34+ hematopoietic progenitors in vitro.
Stimulation of native FLT-3 receptor by its ligand leads to the
immediate activation of phospholipase C-c 1 (PLC-c 1), Ras guano-
sine triphosphatase (GTPase)–activating protein, the p85 subunit
of PI3K, SHC, GRB2, VAV, FYN, and SRC pathways. Of these, PLC-c
1, the p85 subunit of PI3K, SHC, GRB2, and the SRC family kinases
directly associate with the FLT3 cytoplasmic domain. FL stimula-
tion of the native receptor also results in tyrosine phosphorylation
of SHC, SHP-2, and SHIP, which are associated with GAB2 and CBL,respectively. FL stimulation of FLT3 also results in selective JAK-
independent activation of STAT5a. These ﬁndings indicate that
FLT-3/FL signaling is required for at least some of its proliferative
effects during Early B-cell development. However, like SF (c-KIT li-
gand), FL does not efﬁciently induce proliferation of normal mye-
loid and lymphoid progenitors by itself, but strongly synergizes
with other hematopoietic growth factors and interleukins (ILs) [5].
2.6.3. IL-7 signaling
Early lymphocyte development is critically dependent on sig-
nals mediated through the IL-7 receptor. IL-7 signaling mediates
several effects including early B-lymphocyte proliferation, H chain
gene re-arrangements and differentiation. B cell-speciﬁc transcrip-
tion factors E2A and EBF are necessary for initiating B cell differen-
tiation through the cooperative regulation of B cell-speciﬁc genes
such as Rag1, Rag2, Iga, Igb, k5, Vpre-B, CD19 and additionally the
Pax5 gene whose expression renders B cell progenitors irreversibly
committed to the B cell lineage. A direct connection between IL-7
receptor (IL-7R) signaling and up-regulation of EBF expression
demonstrates an indispensable role of IL-7 in the establishment
of transcription factor networks during adult B-cell development.
Numerous studies indicate that deﬁciency of the IL-7R or IL-7
itself leads to an early block in both B and T cell development. Spe-
ciﬁcally, B-cell development in IL-7R/ mice is abrogated at the
pre–pro-B cell and an almost complete absence of pre-B, immature,
and mature B cells. Thus, the IL-7R regulates both early murine
lymphocyte differentiation and proliferation. Reports also show
that in IL-7R/ mice, recombination of VH gene segments is im-
paired indicating its importance in regulating H chain gene recom-
bination facilitated by altering accessibility of this locus to the
recombination-activating gene (Rag) recombinases during early
B-cell development. Flt3 ligand (FL), stem cell factor (SF), and IL-
7 are important cytokines for B-cell development, however, only
IL-7 can promote stage transition from B220+ CD19 pre–pro-B
cells to B220+ CD19+ pro-B cells during early adult B-cell develop-
ment, whereas Flt3 ligand or SF enhances the proliferation of B cell
progenitors in vitro.
The IL-7 Receptor is expressed on common lymphoid progenitor
cells, and includes a unique a chain and a c chain, common to sev-
eral other cytokines, viz. IL-2, IL-4, IL-9, IL-15 and IL-21. Although
Fig. 2. Panel 2a. Key transcription factors involved in B-lymphocyte development. The panel summarizes broad stages of B-lymphocyte development, associating them with
transcription factors (TFs) of particular importance. The stage-speciﬁc developmental blockade in the absence of certain TFs, revealed by conventional gene knockouts are
marked by red loops; and the factors associated with oncogenesis written in red. TFs in black have not yet been reported to be associated with human/mouse haematologic
malignancies. [55,56,59]. Panel 2b. Outline of general protocol. The ﬁgure displays the commonly adopted method for differentiation of B-lymphocytes from haematopoietic
stem cells. Little or no success has been achieved so far in attempts at long-term maintenance and expansion of HSCs in vitro, since they rapidly differentiate in culture.
However, B-lymphocytes can be obtained when multipotent haematopoietic progenitors (MPs) are co-cultured with stromal cell lines (viz., S17 and OP9) in the presence of
soluble growth factors/cytokines (viz., c-kit ligand, IL-7 and Flt-3 ligand). Stromal feeder layers provide yet undeﬁned signals and soluble mediators required for expansion
and/or lineage commitment of multipotent haematopoietic progenitors. Note that more recent studies have revealed non-dependence of MPs on specialized stromal cell lines
and made possible, the use of ﬁbroblast lines (viz., NIH-3T3) for improved control of exogenous cytokine supplementation in culture [60–62].
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ment, the downstream signaling pathways that entrain this pro-
cess remain poorly characterized. IL-7 stimulation of a chain
leads to a-c receptor dimerization and activation of JAK3 associ-
ated with the c chain. Tyrosine phosphorylation of the a chain
by activated JAK3 then serves as a docking site for the recruitment
and activation of the src kinases, PI3K pathway, the Ras/Raf signal-
ing cascade, and JAK/STAT pathways (STAT5 and STAT3) that con-
tribute to cellular proliferation. Some targets of IL-7 signaling
contribute to cellular survival, including Bcl2 and Pyk2. The tran-
scription factor STAT5 contributes to expression of several down-stream auxiliary genes in B and T cells and VDJ gene
rearrangements through alteration of chromatin structure. IL-7 in-
duced cell survival and proliferation act cumulatively in B-cell
development. Similarities in immune defects between JAK3 knock-
out mice and IL-7 knockout mice highlight the importance of JAK3
in IL-7 signaling [6,7].
Although the immediate signaling intermediary molecules and
events appear similar, it is to be noted that the downstream signal-
ing interactome and their ﬁnal transcriptional targets is a resultant
of several possible alternate crosstalk/overlap of pathways to-
gether with the cellular background that ultimately bring about
Fig. 3. Signaling events and interactions in B-cell development and differentiation in vitro. Antigen independent development. The illustration summarizes the downstream
signaling pathways likely to inﬂuence HSC self-renewal, proliferation, and differentiation to B-cells in vivo and in vitro. Three important signals are known to drive
differentiation of multipotent hematopoietic progenitor cells to the B-cell fate (early B-lymphopoiesis) in vitro, viz., c-Kit, Flt-3 and IL-7 pathways. All the three are
structurally similar in that, they all belong to the Ig superfamily of receptors (extracellular Ig-like domains, transmembrane domains and intracellular kinase domains).
Functionally they are all RTKs with split cytoplasmic tyrosine kinase motifs. All of them have also been reported to initiate signals through the SRC family of kinases and/or
the SH-2 Domain containing proteins. At the earliest developmental stage, progenitor-B cells require direct contact with stromal cells. This interaction is mediated by several
CAMs, including VLA-4/VCAM-1 (A). Once a contact is established, stromal-derived or niche-cell-derived steel factor (SF), also known as stem cell factor, brings about
activation of the c-Kit receptor, whose downstream signaling mechanisms ultimately play a role in self-renewal of HSCs in vitro (B). FL (Flt-3 ligand) stimulation of Flt-3
receptor activates several effectors including Jak-independent Stat 5a activation, responsible for some of the proliferative effects of FL on HSCs in vitro (C). IL-7 signaling
cascade, on the other hand, also results in Jak-dependent activation of several members of the STAT group, mainly Stat3 and Stat5, which in turn initiate or switch several
downstream events, imparting signals for VDJ recombination and differentiation within the developing B-lymphocyte (D). Antigen-dependent activation and differentiation.
The B-cell receptor complex (E), is functionally distinguishable, consisting of the antigen-binding membrane-bound immunoglobulin (Ig), the signal transducing Ig-a/Ig-b
[ITAMmotif-containing] heterodimer, and the B-Cell co-receptor [TAPA-1 (CD81), CR2 (CD21) and CD19] (F). Antigen (Ag)-induced cross-linking of the B-cell receptor leads to
activation of signal-transduction pathways for cell proliferation, differentiation and antibody secretion. In one of the common pathways, PLC c2 is tyrosine-phosphorylated by
Syk kinase activity; the former then hydrolyses membrane phospholipids PIP2, to evoke a second messenger (DAG and IP3) response. DAG along with IP3-induced Ca2+
release collaboratively activate PKC, which kick-start several other auxiliary pathways. The activated BCR also initiates the Ras pathway. Activated Ras triggers a cascade of
phosphorylytic activation of signaling intermediates that alter gene expression for effecting structural and functional (differentiation) changes in the cell.
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path of differentiation. Fig. 3 summarizes the downstream signal-
ing pathways that are likely to inﬂuence HSC self-renewal
responses.
3. Signaling mechanisms in vitro. Experimental approaches
towards raising monoclonal antibodies (MAbs) through
in vitro immunizations (IVI)
Several experiments towards generating monoclonal antibodies
have given insights into understanding the various aspects of B-cell
biology. The major areas that are important to this understanding
include apart from the antigen type and dose, the routes of immu-
nization and schedules. The advent of in vitro immunization of
lymphocytes and later on, the aims to standardize protocols for
in vitro boosters of in vivo primed lymphocytes are effective exper-
imental models towards enhancing the understanding of B cellbiology. The following are a few such from both murine and human
lymphocyte models which have revealed speciﬁc signaling mecha-
nisms of in vitro B-cell development.
3.1. Murine in vitro immunizations
The possibility that murine spleenocytes could be activated
in vitro came from the work of Anderson et al. in 1972. They con-
ducted experiments to increase the stimulation of murine spleeno-
cytes by culturing them with normal thymus cells along with a B
cell mitogen [8]. From this and several subsequent experiments
it has been deduced that the addition of T-dependent antigens to
unprimed dissociated mouse spleen cells does not activate the B-
lymphocytes and no signiﬁcant production of antibody is seen.
Several growth factors are required to create efﬁcient stimulatory
environments. The growth supporting conditions can be provided
by the culture of young thymocytes or by mixed lymphocyte
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IFN-c, IL-1 and IL-2. Later, improved techniques were developed to
provide optimum conditions for in vitro activation such as the use
of phorbol myristate acetate ester stimulated EL-4 thymoma cells.
EL-4 derived lymphokines alone had the ability to support an
in vitro immunization 2–3 times better than mixed lymphocyte
culture derived lymphokines [9]. Adjuvant peptide N-acetylmura-
myl-L-alanyl-D-isoglutamine (MDP) and dextran sulfate have also
been reported to improve the yield of speciﬁc hybridomas [10].
Over 50 monoclonal antibodies of murine origin have been devel-
oped from in vitro immunized spleenocytes.
3.2. Human in vitro Immunizations
The use of in vitro immunizations for the development of hu-
man monoclonal antibodies has met with moderate success de-
spite huge efforts by several laboratories [11]. The ﬁrst in vitro
immunization resulting in the production of human monoclonal
antibodies was done in 1984. Sheep red blood cells were used to
stimulate human tonsilar lymphocytes. The method has been ap-
plied to the production of antibodies against other antigens.
3.2.1. Sources of lymphocytes for in vitro immunizations
The tonsils, spleen and peripheral blood are the most commonly
used sources of lymphocytes, each having advantages and disad-
vantages. The spleen is the most popular source for in vitro immu-
nizations because it is a more satisfactory source of antigen speciﬁc
B cells rather than routine tonsillectomy specimens [12]. The
spleenocytes are fractionated into T and B cell populations and
then used for immunization in cultures. The methods of separation
vary from rosetting to separation using speciﬁc antibodies or FACS
methods. A combination of T helper cells and B cells in the ratio of
at least 0.4 is then cultured in medium containing serum along
with the required lymphokines and the antigen [13]. Methods have
also been described where the cells are not separated into fractions
and allogeneic, endogenous stimulation is used in the place of sup-
plementation with puriﬁed lymphokines. Immunizations of
spleenocytes usually results in the production of IgM. However, if
memory cells in the spleen get stimulated, then IgG may be pro-
duced. The memory cells may have been developed due to the
prior exposure to an antigen similar to that used for the in vitro
immunization. This cross reactive stimulation known as ‘original
antigenic sin’ occurs in vitro due to the loss of suppressive and reg-
ulatory inﬂuences [14].
3.3. In vitro stimulation of in vivo primed lymphocytes
Lymphocytes from individuals who have been sensitized to a
particular antigen in vivo have been stimulated in vitro. Stimula-
tion can be achieved using a polyclonal B cell activator such as
pokeweed mitogen (PWM) or the speciﬁc antigen itself. The trig-
gering of cells in vitro after booster immunization has been found
to increase the efﬁciency of monoclonal antibody production [15].
In such experiments, it was found that the kinetics of the circulat-
ing lymphocytes was very important. Six to eight days after boos-
ter immunizations, antibody producing cells can be found in
peripheral circulation. But at 14 days, the number of these cells
shows a rapid decline to baseline values. It is seen that as long as
the antigen speciﬁc B cells that are formed during in vivo immuni-
zations are found in culture, they can be triggered in vitro to pro-
duce antibodies of appreciable titre. Further, it has also been
postulated that every antigenic stimulation event is associated
with a polyclonal response [16]. The dichotomy between antibod-
ies produced by stimulation with mitogens and with speciﬁc anti-
gen is determined by several conditions such as the antigenic
concentration, cell density and cell culture surfaces. High antigenconcentrations cause speciﬁc suppression of antibody production
by the in vivo primed lymphocytes stimulated in vitro [17].
3.4. In vitro immunizations using T-dependent antigens
Polyclonal B cell activators are T-independent antigens and
hence are probably capable of more efﬁcient B cell activation
in vitro. The steps leading towards production of antibodies against
T-dependent antigens are however far more complicated. Ficoll
isolated peripheral blood lymphocytes can be separated into the
various fractions – the T, B and accessory cells. Irradiation of the
T lymphocyte population results in destruction of the T suppressor
cells and hence a T helper cell enriched population can be obtained.
The accessory cell population is composed mainly of dendritic cells
which are necessary for antigen presentation to T cells. There is a
discrepancy in the ratio of cells that is suitable for immunizations.
It varies from 1:0.2 to 1:5 of T cells to B cells [18]. When accessory
cells are also added in the B/A/T ratio of 1:2:0.4, greater efﬁciency
is achieved [19]. It has also been found that overnight incubation of
T helper cells with the dendritic cells in the presence of indometh-
acin and IFN-c increases T helper cell activation and thus B cell
stimulation [20].
The use of un-primed lymphocytes for in vitro immunization
poses an even greater challenge. One of the main criteria for immu-
nizations is that the cell density should be high so as to facilitate
cell–cell interactions. The use of the Marbrook chamber helps over-
come this problem. It consists of a glass tube closed by a mem-
brane with the lower end of the tube dipping into a recipient
glass bottle. Up to 5  107 cells can be cultivated in the chamber
owing to the continuous exchange of metabolic products for nutri-
ents through the membrane. The chamber maintains the cells in
high concentrations in a small area and is found to increase the
survival rate of the lymphocytes to 50% [11].
3.5. Effect of growth factors on in vitro immunizations
The source of lymphokines used to supplement medium during
culture has been varied across reports. Syngenic heat inactivated
serum is commonly used during immunizations.
It is known that the activation of B-lymphocytes with a T-
dependent antigen requires T helper cells. The T derived help fac-
tors can be obtained from irradiated T cells that are grown in the
presence of mitogens (usually PWM). PWM induced T cell replac-
ing factor (PWM-TRF) which is a BCDF obtained from such a cul-
ture is necessary for an optimal response from B-lymphocytes
in vitro, as proved by Danielsson et al. Antigen speciﬁc activation
was improved by tonsilar BCDF and recombinant IL-2 [20]. Some
investigators have however reported that the addition of mitogens
directly to the supernatants is effective in activation of the B cells
[18].
3.6. Role of CD 40 in the activation of B cells
The interaction between CD 40 receptor on the B cell surface
and its complementary ligand on the T cell is one of the hallmarks
of T-dependent B cell activation. It is also required for isotype
switching. Human B cells can be activated and induced to prolifer-
ate in vitro by triggering their surface receptor CD 40 in the pres-
ence of IL-4. One such method uses mouse cells transfected with
human Fc receptor for anti-CD 40 antibody, coated on a solid sur-
face followed by irradiation to prevent their proliferation. CD 40 is
then added which binds to the Fc receptor. The B-lymphocytes
bind to the CD 40 antibody which promotes progression to G1
phase of the cell cycle. This causes an increase in the B cell popu-
lation by 20% within two weeks [19]. Mice transfected with the
CD 40 L have also been used in the same way [15].
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in peripheral blood
Peripheral blood B-lymphocytes are said to be under suppres-
sion due to the presence of large granular lymphocytes, cytotoxic
and suppressor T cells. Such a condition prevents the effective acti-
vation of B cells. Cells mediating cytotoxic immune responses are
known to contain pore-forming enzymes, serine esterases, TNFs
which are found in lysosome-like granules of natural killer cells
and cytotoxic T lymphocytes. An accumulation of L-amino acid es-
ters in the lysosomes of cytotoxic cells causes them to swell and
rupture, releasing the enzymes and esterases that would destroy
neighbouring cells. Efforts to delete the cytotoxic population of
lymphocytes led to the discovery of the L-leucine methyl (Leu-
OMe) ester and its derivative L-leucyl-L-leucine methyl ester
(Leu-Leu-OMe). The mechanisms involved in the action of the ester
are dependent on the conversion of Leu-Leu-OMe to membranolyt-
ic products by the acyl transferase activity of cathepsin C [21].
These esters speciﬁcally target cytotoxic cells and monocytes but
leave T helper cells, B-lymphocytes, dendritic cells and ﬁbroblasts
unaffected. The treatment of peripheral blood lymphocytes with
Leu-OMe results in a 72% recovery of cells. A concentration of
2.5 mM Leu-OMe is usually added followed by 40 min incubation.
Further, if the separated lymphocytes were treated with the ester,
a 10-fold increase in the number of antibody producing cells was
seen [17]. Other lysosomotropic substances are yet to be identiﬁed.
There are several regulatory mechanisms active in the periphe-
ral blood lymphocyte population. There are still a number of cyto-
kines which are required for activation and proliferation of B cells
in vivo which have not been studied with respect to in vitro immu-
nizations. The response of B and T cells is also regulated by antigen
excess. Higher antigen concentrations have shown to bring about a
suppression of B cell activation in vitro by both T-dependent and T-
independent antigens [16]. Since a concentration of 10–500 ng/ml
of antigen is the range reported for in vitro immunizations, [22]
further studies on the immunoregulation by antigen concentration
is required. The complex pattern of cellular interactions in periph-
eral blood lymphocytes also is important. This includes the under-
standing of mechanisms involved in cytotoxic and T suppressor
cell down-regulation of B cells, the nature of T helper-B cell inter-
action and antigen presentation by accessory cells.
The isotype of antibody produced by in vitro immunizations are
usually IgM. There is very little understanding regarding the class
switch in vitro and the events that lead to afﬁnity maturation.
The interaction of CD 40 and CD 40L is known to be necessary
for class switching. Wohlleben et al. utilized the spleen cells from
Balb/C mice transfected with CD 40L. Subsequent culture of spleen
cells expressing CD 40L primed B-lymphocytes did not bring about
a class switch of the antibodies produced by the lymphocytes as
expected. Zaﬁropoulos et al. tried to mimic the conditions present
in the germinal centres of lymphoid organs to bring about class
switching of antibodies produced by in vitro immunizations. They
used an antigenic construct containing both T and B-lymphocyte
epitopes of tetanus toxoid; and T cells from individuals with mem-
ory response to tetanus toxoid in a CD 40 modiﬁed system. The
system was able to induce a class switch in vitro [23]. Site directed
mutagenesis increases the afﬁnity of an antibody eight times and
decreases its cross reactivity [22].4. Non-antigenic stimulations for the B-cell development
in vitro
Mitogenic in vitro stimulation of murine as well as human B and
T lymphocytes triggers gene expression through activated signal-
ing mechanisms. These mechanisms lead to protein productionand polyclonal cell proliferation followed by further differentia-
tion. Mitogens function different from immunogens in that poly-
clonal activators can stimulate several B or T cell clones
irrespective of their antigenic speciﬁcities [24]. Also due to the fact
that the mitogens are speciﬁc to the lymphocyte lineage stimu-
lated, they are often exploited as cell origin markers [25]. Lectins,
a class of sugar-binding proteins, have some well characterized
members like Concanavalin-A (Con-A) and Phytoheamoagglutin
(PHA) that act as effective T cell mitogens as they do not stimulate
cell suspensions lacking T-lymphocytes. However, Poke Weed
Mitogen (PWM) another potent mitogenic lectin, stimulates poly-
clonal activation of both B- and T-lymphocytes in culture [24]
while lipopolysaccharides (LPS), a protein–free endotoxin from
gram negative bacteria was proven to speciﬁcally stimulate murine
B-lymphocytes and activate human peripheral blood lymphocytes
only when cultured under special conditions. Peptidoglycans (PG)
are another class of chemically well established T cell and macro-
phage independent, highly active mitogens of mice and human
lymphocytes. They can activate human T- and B-lymphocytes from
peripheral blood quite readily and possess an effective blast induc-
tion property when present in cultures for over 24 h [26]. Thus, the
stimulatory effects vary depending on factors such as the choice of
the mitogen, cell population and culture conditions [27].
Mitogenic proteins from PWM are suitable stimulants for stud-
ies of in vitro activation of Human B-lymphocytes as they can elicit
B cell responses and synthesize sufﬁcient amounts of IgG in human
lymphocytes [28], although stimulation of B-cells with PWM may
not always be reproducible [29]. This can be attributed to the mul-
titude of the components extracted from mitogenic proteins (Pa1–
Pa5) of the pokeweed extract by gel ﬁltration chromatography
[30]. The Pa1 fraction has been shown to possess the ability to
stimulate B-cells in murine spleen cell culture, while Pa2 a potent
T cell mitogen is thought to stimulate B-cells through activated T
cells as well as through a weak direct effect on B-cells [28]. Both
PHA and PWM stimulated human B and T cell populations could
release mitogenic factors (MF). However, Sepharose bound Con-A
could trigger the release of much higher amounts of MF exclusive
of T cells or lymphocyte suspensions [31].
It has been seen that there may be requirement of both T cell
mitogen and T-helper activity for human peripheral blood B-lym-
phocyte antibody secretion [25,28,32,33] whereas a direct interac-
tion with an activator molecule could stimulate murine B-
lymphocytes in culture [34,35]. Long term growth of B cells
in vitro has been accomplished by the presence of ‘soluble factors’
capable of stimulating B cells that are thought to be secreted by an
adherent stromal layer that comprised of Reticulo-endothelial
cells, ﬁbroblasts, epithelial-like cells and mononuclear cells [36].
For optimal development of plasma cells in mitogen induced
in vitro cultures, proper choice of serum supplement, medium,
and density of cells amongst other conditions must be considered
[28]. It is recommended that expression with cell lineage speciﬁc
mitogens must be considered taking into account the cell–cell
interactions as well [25].
Con-A originally isolated from Jack bean (Canavalia ensiformis)
has a powerful mitogenic activity [37]. Tritiated thymidine uptake
studies have demonstrated that lymphocytes stimulated by Con-A
secrete a factor that in turn could stimulate fresh lymphocyte cul-
tures to actively synthesize DNA [38]. Con-A is a tetramer with four
subunits of molecular weight 27 kDa and one saccharide binding
site whose binding targets have been found to be a-D-mannopyr-
anosyl, a and b-D-glucopyranosyl and b-D-fructofuranosyl groups
[38]. The tetravalency of Con-A has lead researchers to believe its
involvement in the receptor-crosslinkage required for the lympho-
cyte stimulation leading to blast formation and DNA synthesis [39].
Its interaction with sugar residues of carbohydrate non-reducing
side chains causes it to bind strongly to Sephadex [37]. Con-A
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Allogenic Helper Factors (AHF) although insoluble Con-A could di-
rectly induce B cell proliferation [40]. Moreover, Con-A was known
to induce mouse T cells but not B cells in spite of similar binding
afﬁnities to both [41]. It was later shown that it could induce puri-
ﬁed B cells of murine origin to depolarize and enlarge but not in-
duce DNA synthesis [42]. A ‘double effect’ of Con-A on B cells has
been described in one study where ﬁrstly, they are involved in
cross-linking of glycosylated surface-bound IgM [43] and secondly
in rendering the cells responsive to both B and T cell derived helper
factors. In all cases Con-A presence at the start of cell culture initi-
ation is thought to help in stimulating maximal lymphocyte re-
sponse [44].
In vitro activation of naïve B-lymphocytes to plasma cells require
various stimulatory conditions apart from stimulation by T-helper
cells. Furthermore, theproductionof different immunoglobulin sub-
types requires unique isotype speciﬁc stimulatory conditions. For
example, the production of IgE producing plasma cells require T cell
clones activated by anti-CD3mAb or PHA [45] while the production
of IgM requires the provision of appropriate Th activities with or
without stimulation by polyclonal activators such as PWM [46]. In
our studies,wehave seen that boundCon-A can stimulate the prolif-
eration and production of IgG producing plasma cells from periphe-
ral blood naïve B-lymphocytes. Furthermore, under culture
conditions of total mononucleate cell population supplemented
with 5% FBS, 20% conditionedmedium fromhumanmultiplemyelo-
maU266 cultures and 20% autologous serum, proliferationwas seen
to increase 10-fold. We also observed that cultures supplemented
with 5% FBS alone gave cells with the maximal secretory propertyFig. 4. Peripheral blood mononucleate cells when subjected to Concanavalin A boun
supplementing the cultures with heat inactivated autologous serum, FBS and condition
combinations of the three supplements was studied for the single or synergistic effect for
effects of CAB on B cells. The panel shows the cultures at various days of incubation with
cells to CAB at the initiation of cultures. It is presumed that all cells bound are mIg+. (
morphologies as typical of physiologically active circulatory cell types in culture; after 6
CABs. (C) The progressive cell detachments indicate the loss of membrane-bound IgG wh
The cells and the beads are distinct owing to their size differences. (D) The cells do no
ﬂowcytometric enumeration and relative grading of cell densities and cell health in cul
supplements used. Maximum yield of plasma cells were obtained from cultures contain
density of cells in peak health.(Fig. 4). This seems to indicate that bound Con-A as well as factors
present in FBS are the isotype speciﬁc conditions required for IgG
production. One reason for this has seen to be due to the production
of B cell replication and maturation factors by T cells [31,47].
Cross linking of cognate antigen receptors is an absolute neces-
sity even for the in vitro differentiation of naïve B cells apart from
antigenic recognition [48]. These receptors include in addition to
the B cell receptors (BCR), also the toll-like receptors (TLR) [49].
In addition, the mechanism of antigenic stimulation must also in-
clude the multiple valence of antigen–cell interactions. A role for
multivalent interactions between an antigen and cell receptors
can be inferred from the lack of a correlation between antibody
afﬁnity for a determinant and the antigen concentration required
to stimulate its production. Thus, while many immunoglobulins
and cells with immunoglobulin receptors bind antigens with en-
hanced avidity as a result of multivalent interactions, only those
cells whose receptors are of relatively high afﬁnity will be stimu-
lated by the bound antigen.
For example, Con-A in the bound form is seen to cause an en-
hanced lymphocyte proliferation effect [31]. This ‘‘helper” effect
however, is seen to be true only in cases of cultures performed at
low cell concentration particularly that of T blasts, with suboptimal
doses of lectin [50], an observation that our experiments have also
substantiated. While in the unbound form, Con-A is seen to pri-
marily have a non-cytotoxic, suppressive effect on B cell immuno-
globulin production. The mechanism involved in this suppressive
effect seems to be due to the production of certain inhibitory cyto-
kines by Con-A activated T cells that act either directly on the B
cells or through monocytes [51]. Non-antigenic stimulation of Bd agarose beads show marked developments in culture. This is augmented with
ed medium from U266 cell cultures. Supplementing cultures with different ratio
B-cell development. This is also to study the factors that can enhance the mitogenic
progressive cell detachments to the CABs. (A) Shows the maximum attachment of
B) Shows the increased cell density in culture with free cells showing differential
days in culture. This stage is characterized by maximal cell detachments from the
ich is indicative of the activation and differentiation of the cells during the culture.
t survive beyond 12 days in culture. Intracytoplasmic staining for IgG followed by
tures was performed for the cultures with various ratio combinations of the three
ing all three supplements and such cultures were also seen to have maximum cell
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seen in the case of viral infection of B cells. Such a stimulatory ef-
fect therefore, does not require lymphocyte interactions [52,53].
Experiments proving the same, could give insights into the means
exploited by infectious viruses to inhibit the normal humoral re-
sponse. In vitro studies thus indicate that B cell activation requires
antigens with a unique molecular structure not limited singly by
polymeric repeating determinants or a polyanionic nature but also
by a minimum molecular weight of the antigen [53].5. Conclusion
In this review, we have discussed B-lymphocyte development,
both in vivo and in vitro, with a focus on the complex interplay be-
tween ligand–receptor interactions; signaling events and mecha-
nisms, and the key transcription factors network along the
developmental path. We have described the experimental ﬁndings
of several independent groups, including our own, that shed light
on mechanisms of B-cell activation, differentiation and antibody
generation in vitro in both murine and human model systems.
Although long-term maintenance and expansion of self-renewing
multipotent HSCs in vitro has met with meager success due to their
rapid differentiation in culture attributed to our incomplete under-
standing of the haematopoietic niche, methods exist for directed
differentiation of multipotent haematopoietic progenitors along
the B lineage, by means of stromal co-cultures/feeders, which pro-
vide yet undeﬁned signals and soluble mediators required for sur-
vival, expansion and lineage commitment of the multipotent
progenitors. The changing expression pattern of cell surface mark-
ers that typify the developmental progression from Stem/progeni-
tor to mature cell deserves a special mention, as their
characterization has served as a valuable tool for developmental
stage identiﬁcation, FACS-based cell isolation procedures and for
their diagnostic utility. In vitro immunizations for MAb/Hybridoma
generation have been the method of choice in constraints like poor
antigen availability and time. The different sources of lymphocytes
exploited include tonsils, spleen and peripheral blood. Originally
established methods employ isolated B-lymphocyte cultures in
conditioned medium, supplemented with growth and differentia-
tion factors for their activation, while further methodical enhance-
ments and complementary extensions of original protocols came
with the inclusion of supportive T-helper and accessory dendritic
cell populations in empirically established ratios in culture, efforts
to decrease undesirable T-suppressor and T-cytotoxic cell effects in
culture, several additives for activation like phorbol myristate ace-
tate esters, adjuvant peptides like N-acetylmuramyl-L-alanyl-D-iso-
glutamine (MDP), dextran sulfate for select hybridoma yield
improvement, etc., detailed herein. In vitro stimulation of in vivo
immunized B-lymphocytes provides the advantage of memory re-
sponse (secondary) for weak immunogens. The effects and utility
of mitogenic-stimulation (e.g., Con-A, PHA, PWM) compared to
speciﬁc antigenic-stimulation has also been reviewed within the
scope of this review.
More recent advances in tissue culture technology, viz., 3D cul-
ture systems have facilitated better characterization of the haema-
topoietic microenvironment and continue to aid in the discovery of
novel soluble and membrane-bound niche factors implicated in
HSC maintenance and B-cell development, summarily enabling
greater external control of culture conditions, and has led to cer-
tain invaluable contribution to the ﬁeld of regenerative medicine
and existing HSC therapies.
The immune system, only second after the Nervous system in
complexity, has posed formidable challenges in its studies over
several decades, but has remained a subject of prime interest to
biologists/medical researchers, because of the far-ranging applica-tions of antibodies, the work-horses of the immune system, in
diagnosis (agglutination precipitation ELISA-based blotting), re-
search (IHC, Flow A Cytometry S, Confocal and live imaging) and
therapy (MAb therapies for cancer, atherosclerosis, autoimmunity
etc.). Human Antibody therapeutics has gained much emphasis
over the last decade, particularly in therapy for chronic diseases
like cancer and in combating viral diseases.
Infectious agents continue to pose a constant threat to the lives
of people. This stimulated sustained and meaningful efforts to-
wards progress not only in several laboratories to create human
antibodies of diagnostic, clinical or research importance, but also
in establishing large scale tissue culture-based production facilities
for potentially important therapeutic antibodies. This aims to pro-
vide quality biologicals keeping in mind, safety, efﬁcacy, extended
availability and affordability, on a pursuit to fulﬁll this need leav-
ing us with hope for effective curative therapies in future. The re-
view on the B cells encompassing all the important aspects will
sure help us in this direction.
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